Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors.

CONCLUSIONS: MK-4166 900 mg IV Q3W as monotherapy and with pembrolizumab was tolerable. Responses were observed with combination therapy, mostly in patients with ICI-naive melanoma. PMID: 33355238 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33355238?dopt=Abstract

Source: Clinical Cancer Research - December 21, 2020 Category: Cancer & Oncology Authors: Papadopoulos KP, Autio KA, Golan T, Dobrenkov K, Chartash E, Chen Q, Wnek R, Long GV Tags: Clin Cancer Res Source Type: research